;PMID: 7512175
;source_file_796.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..30] = [t:0..30]
;1)sentence:[e:35..115] = [t:35..115]
;2)section:[e:119..171] = [t:119..171]
;3)section:[e:175..292] = [t:175..292]
;4)sentence:[e:296..453] = [t:296..453]
;5)sentence:[e:455..692] = [t:455..692]
;6)sentence:[e:694..994] = [t:694..994]
;7)sentence:[e:995..1111] = [t:995..1111]
;8)sentence:[e:1112..1317] = [t:1112..1317]
;9)sentence:[e:1318..1397] = [t:1318..1397]
;10)sentence:[e:1398..1560] = [t:1398..1560]
;11)sentence:[e:1562..1751] = [t:1562..1751]
;12)section:[e:1755..1799] = [t:1755..1799]

;section 0 Span:0..30
;Leukemia  1994 Apr;8(4):638-41
(SEC
  (FRAG (NNP:[0..8] Leukemia) (CD:[10..14] 1994) (.:[15..21] Apr;8-LRB-)
        (CD:[21..23] 4-RRB-) (CD:[23..27] :638) (::[27..28] -) (CD:[28..30] 41)))

;sentence 1 Span:35..115
;Mutations in the ras proto-oncogenes in patients with myelodysplastic
;syndromes.
;[52..55]:gene-rna:"ras"
;[89..114]:malignancy:"myelodysplastic syndromes"
(SENT
  (NP-HLN
    (NP (NNS:[35..44] Mutations))
    (PP-LOC (IN:[45..47] in)
      (NP (DT:[48..51] the) (NN:[52..55] ras) (AFX:[56..61] proto)
          (HYPH:[61..62] -) (NNS:[62..71] oncogenes)))
    (PP-LOC (IN:[72..74] in)
      (NP
        (NP (NNS:[75..83] patients))
        (PP (IN:[84..88] with)
          (NP (JJ:[89..104] myelodysplastic) (NNS:[105..114] syndromes)))))
    (.:[114..115] .)))

;section 2 Span:119..171
;Neubauer A, Greenberg P, Negrin R, Ginzton N, Liu E.
(SEC
  (FRAG (NNP:[119..127] Neubauer) (NNP:[128..129] A) (,:[129..130] ,)
        (NNP:[131..140] Greenberg) (NNP:[141..142] P) (,:[142..143] ,)
        (NNP:[144..150] Negrin) (NNP:[151..153] R,) (NNP:[154..161] Ginzton)
        (NNP:[162..163] N) (,:[163..164] ,) (NNP:[165..168] Liu)
        (NNP:[169..171] E.)))

;section 3 Span:175..292
;Department of Medicine and Genetics, Lineberger Cancer Research Center, 
;University of North Carolina at Chapel Hill.
(SEC
  (FRAG (NNP:[175..185] Department) (IN:[186..188] of) (NN:[189..197] Medicine)
        (CC:[198..201] and) (NNP:[202..210] Genetics) (NNP:[210..211] ,)
        (NNP:[212..222] Lineberger) (NNP:[223..229] Cancer)
        (NNP:[230..238] Research) (NNP:[239..245] Center) (,:[245..246] ,)
        (NNP:[248..258] University) (IN:[259..261] of) (NNP:[262..267] North)
        (NNP:[268..276] Carolina) (IN:[277..279] at) (NNP:[280..286] Chapel)
        (NNP:[287..291] Hill) (.:[291..292] .)))

;sentence 4 Span:296..453
;Activation of the N- and K-ras proto-oncogenes is the most common molecular 
;abnormality in myelodysplastic syndromes (MDS) and acute myeloid leukemia
;(AML).
;[314..316]...[323..326]:gene-rna:"N-"..."ras"
;[321..326]:gene-rna:"K-ras"
;[388..413]:malignancy:"myelodysplastic syndromes"
;[415..418]:malignancy:"MDS"
;[424..446]:malignancy:"acute myeloid leukemia"
;[448..451]:malignancy:"AML"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[296..306] Activation))
      (PP (IN:[307..309] of)
        (NP (DT:[310..313] the)
          (NML
            (NML
              (NML (NN:[314..315] N) (HYPH:[315..316] -)
                (NML-1 (-NONE-:[316..316] *P*)))
              (NML-2 (-NONE-:[316..316] *P*)))
            (CC:[317..320] and)
            (NML
              (NML (NN:[321..322] K) (HYPH:[322..323] -)
                (NML-1 (NN:[323..326] ras)))
              (NML-2 (AFX:[327..332] proto) (HYPH:[332..333] -)
                     (NNS:[333..342] oncogenes)))))))
    (VP (VBZ:[343..345] is)
      (NP-PRD (DT:[346..349] the)
        (ADJP (RBS:[350..354] most) (JJ:[355..361] common))
        (JJ:[362..371] molecular) (NN:[373..384] abnormality))
      (PP (IN:[385..387] in)
        (NP
          (NP
            (NP (JJ:[388..403] myelodysplastic) (NNS:[404..413] syndromes))
            (NP (-LRB-:[414..415] -LRB-) (NN:[415..418] MDS)
                (-RRB-:[418..419] -RRB-)))
          (CC:[420..423] and)
          (NP
            (NP (JJ:[424..429] acute) (JJ:[430..437] myeloid)
                (NN:[438..446] leukemia))
            (NP (-LRB-:[447..448] -LRB-) (NN:[448..451] AML)
                (-RRB-:[451..452] -RRB-))))))
    (.:[452..453] .)))

;sentence 5 Span:455..692
;In retrospective studies, approximately 3-36% of MDS patients were reported
;to  harbor a mutated ras proto-oncogene, with some series suggesting the
;presence of  ras-mutations are associated with progressive disease and a poor
;prognosis.
;[504..507]:malignancy:"MDS"
;[552..555]:gene-rna:"ras"
;[617..620]:gene-rna:"ras"
(SENT
  (S
    (PP (IN:[455..457] In)
      (NP (JJ:[458..471] retrospective) (NNS:[472..479] studies)))
    (,:[479..480] ,)
    (NP-SBJ-2
      (NP
        (QP (RB:[481..494] approximately) (CD:[495..496] 3) (HYPH:[496..497] -)
            (CD:[497..499] 36))
        (NN:[499..500] %))
      (PP (IN:[501..503] of)
        (NP (NN:[504..507] MDS) (NNS:[508..516] patients))))
    (VP (VBD:[517..521] were)
      (VP (VBN:[522..530] reported)
        (S
          (NP-SBJ-2 (-NONE-:[530..530] *))
          (VP (TO:[531..533] to)
            (VP (VB:[535..541] harbor)
              (NP (DT:[542..543] a) (JJ:[544..551] mutated) (NN:[552..555] ras)
                  (AFX:[556..561] proto) (HYPH:[561..562] -)
                  (NN:[562..570] oncogene)))))
        (,:[570..571] ,)
        (PP (IN:[572..576] with)
          (S-NOM
            (NP-SBJ (DT:[577..581] some) (NNS:[582..588] series))
            (VP (VBG:[589..599] suggesting)
              (SBAR (-NONE-:[599..599] 0)
                (S
                  (NP-SBJ-1
                    (NP (DT:[600..603] the) (NN:[604..612] presence))
                    (PP (IN:[613..615] of)
                      (NP (NN:[617..620] ras) (HYPH:[620..621] -)
                          (NNS:[621..630] mutations))))
                  (VP (VBP:[631..634] are)
                    (VP (JJ:[635..645] associated)
                      (NP-1 (-NONE-:[645..645] *))
                      (PP-CLR (IN:[646..650] with)
                        (NP
                          (NP (JJ:[651..662] progressive)
                              (NN:[663..670] disease))
                          (CC:[671..674] and)
                          (NP (DT:[675..676] a) (JJ:[677..681] poor)
                              (NN:[682..691] prognosis)))))))))))))
    (.:[691..692] .)))

;sentence 6 Span:694..994
;Since hematopoietic growth factors such as granulocyte colony-stimulating
;factor  (G-CSF) are currently used for therapy in MDS but may stimulate the 
;proliferation of leukemic cells, we assessed the frequency and significance
;of  ras mutations in 27 MDS patients, 15 of whom underwent G-CSF therapy.
;[700..728]:gene-protein:"hematopoietic growth factors"
;[737..774]:gene-protein:"granulocyte colony-stimulating factor"
;[777..782]:gene-protein:"G-CSF"
;[818..821]:malignancy:"MDS"
;[862..876]:malignancy:"leukemic cells"
;[925..928]:gene-rna:"ras"
;[945..948]:malignancy:"MDS"
;[980..985]:gene-protein:"G-CSF"
(SENT
  (S
    (SBAR-ADV (IN:[694..699] Since)
      (S
        (NP-SBJ-1
          (NP (JJ:[700..713] hematopoietic) (NN:[714..720] growth)
              (NNS:[721..728] factors))
          (PP (JJ:[729..733] such) (IN:[734..736] as)
            (NP
              (NP (NN:[737..748] granulocyte)
                (NML (NN:[749..755] colony) (HYPH:[755..756] -)
                     (VBG:[756..767] stimulating))
                (NN:[768..774] factor))
              (NP (-LRB-:[776..777] -LRB-) (NN:[777..782] G-CSF)
                  (-RRB-:[782..783] -RRB-)))))
        (VP
          (VP (VBP:[784..787] are)
            (ADVP-TMP (RB:[788..797] currently))
            (VP (VBN:[798..802] used)
              (NP-1 (-NONE-:[802..802] *))
              (PP (IN:[803..806] for)
                (NP (NN:[807..814] therapy)))
              (PP (IN:[815..817] in)
                (NP (NN:[818..821] MDS)))))
          (CC:[822..825] but)
          (VP (MD:[826..829] may)
            (VP (VB:[830..839] stimulate)
              (NP
                (NP (DT:[840..843] the) (NN:[845..858] proliferation))
                (PP (IN:[859..861] of)
                  (NP (JJ:[862..870] leukemic) (NNS:[871..876] cells)))))))))
    (,:[876..877] ,)
    (NP-SBJ (PRP:[878..880] we))
    (VP (VBD:[881..889] assessed)
      (NP
        (NP
          (NP (DT:[890..893] the) (NN:[894..903] frequency))
          (CC:[904..907] and)
          (NP (NN:[908..920] significance)))
        (PP (IN:[921..923] of)
          (NP
            (NP (NN:[925..928] ras) (NNS:[929..938] mutations))
            (PP (IN:[939..941] in)
              (NP
                (NP (CD:[942..944] 27) (NN:[945..948] MDS)
                    (NNS:[949..957] patients))
                (,:[957..958] ,)
                (SBAR
                  (WHNP-2
                    (NP (CD:[959..961] 15))
                    (WHPP (IN:[962..964] of)
                      (WHNP (WP:[965..969] whom))))
                  (S
                    (NP-SBJ-2 (-NONE-:[969..969] *T*))
                    (VP (VBD:[970..979] underwent)
                      (NP (NN:[980..985] G-CSF) (NN:[986..993] therapy)))))))))))
    (.:[993..994] .)))

;sentence 7 Span:995..1111
;Patients  were analyzed for the presence of mutations in codons 12, 13, and
;61 of the N-  and K-ras proto-oncogenes.
;[1039..1048]:variation-event:"mutations"
;[1052..1061]:variation-location:"codons 12"
;[1052..1058]...[1071..1073]:variation-location:"codons"..."61"
;[1052..1058]...[1063..1065]:variation-location:"codons"..."13"
;[1081..1083]...[1091..1094]:gene-rna:"N-"..."ras"
;[1089..1094]:gene-rna:"K-ras"
(SENT
  (S
    (NP-SBJ-1 (NNS:[995..1003] Patients))
    (VP (VBD:[1005..1009] were)
      (VP (VBN:[1010..1018] analyzed)
        (NP-1 (-NONE-:[1018..1018] *))
        (PP (IN:[1019..1022] for)
          (NP
            (NP (DT:[1023..1026] the) (NN:[1027..1035] presence))
            (PP (IN:[1036..1038] of)
              (NP
                (NP (NNS:[1039..1048] mutations))
                (PP-LOC (IN:[1049..1051] in)
                  (NP
                    (NP
                      (NP
                        (NML-2 (NNS:[1052..1058] codons))
                        (CD:[1059..1061] 12))
                      (,:[1061..1062] ,)
                      (NP
                        (NML-2 (-NONE-:[1062..1062] *P*))
                        (CD:[1063..1065] 13))
                      (,:[1065..1066] ,) (CC:[1067..1070] and)
                      (NP
                        (NML-2 (-NONE-:[1070..1070] *P*))
                        (CD:[1071..1073] 61)))
                    (PP (IN:[1074..1076] of)
                      (NP (DT:[1077..1080] the)
                        (NML
                          (NML
                            (NML (NN:[1081..1082] N) (HYPH:[1082..1083] -)
                              (NML-3 (-NONE-:[1083..1083] *P*)))
                            (NML-4 (-NONE-:[1083..1083] *P*)))
                          (CC:[1085..1088] and)
                          (NML
                            (NML (NN:[1089..1090] K) (HYPH:[1090..1091] -)
                              (NML-3 (NN:[1091..1094] ras)))
                            (NML-4 (AFX:[1095..1100] proto)
                                   (HYPH:[1100..1101] -)
                                   (NNS:[1101..1110] oncogenes))))))))))))))
    (.:[1110..1111] .)))

;sentence 8 Span:1112..1317
;Only three patients (11%, two refractory anemia with  excess of blasts
;(RAEB), one RAEB in transformation (RAEB-T)) harbored activated  ras
;oncogenes with the mutations localized in N-ras codons 12 and 61.
;[1142..1182]:malignancy:"refractory anemia with  excess of blasts"
;[1184..1188]:malignancy:"RAEB"
;[1195..1217]:malignancy:"RAEB in transformation"
;[1219..1225]:malignancy:"RAEB-T"
;[1248..1251]:gene-rna:"ras"
;[1271..1280]:variation-event:"mutations"
;[1294..1299]:gene-rna:"N-ras"
;[1300..1309]:variation-location:"codons 12"
;[1300..1306]...[1314..1316]:variation-location:"codons"..."61"
(SENT
  (S
    (NP-SBJ (RB:[1112..1116] Only) (CD:[1117..1122] three)
            (NNS:[1123..1131] patients)
      (PRN (-LRB-:[1132..1133] -LRB-)
        (FRAG
          (NP (CD:[1133..1135] 11) (NN:[1135..1136] %))
          (,:[1136..1137] ,)
          (NP (CD:[1138..1141] two)
            (NML
              (NML
                (NML (JJ:[1142..1152] refractory) (NN:[1153..1159] anemia))
                (PP (IN:[1160..1164] with)
                  (NP
                    (NP (NN:[1166..1172] excess))
                    (PP (IN:[1173..1175] of)
                      (NP (NNS:[1176..1182] blasts))))))
              (NML (-LRB-:[1183..1184] -LRB-) (NN:[1184..1188] RAEB)
                   (-RRB-:[1188..1189] -RRB-))))
          (,:[1189..1190] ,)
          (NP (CD:[1191..1194] one)
            (NML
              (NML
                (NML (NN:[1195..1199] RAEB))
                (PP (IN:[1200..1202] in)
                  (NP (NN:[1203..1217] transformation))))
              (NML (-LRB-:[1218..1219] -LRB-) (NN:[1219..1225] RAEB-T)
                   (-RRB-:[1225..1226] -RRB-)))))
        (-RRB-:[1226..1227] -RRB-)))
    (VP (VBD:[1228..1236] harbored)
      (NP (JJ:[1237..1246] activated) (NN:[1248..1251] ras)
          (NNS:[1252..1261] oncogenes))
      (PP (IN:[1262..1266] with)
        (S-NOM
          (NP-SBJ (DT:[1267..1270] the) (NNS:[1271..1280] mutations))
          (VP (VBN:[1281..1290] localized)
            (PP-LOC (IN:[1291..1293] in)
              (NP
                (NP
                  (NML-2 (NN:[1294..1299] N-ras))
                  (NML
                    (NML-1 (NNS:[1300..1306] codons))
                    (CD:[1307..1309] 12)))
                (CC:[1310..1313] and)
                (NP
                  (NML-2 (-NONE-:[1313..1313] *P*))
                  (NML
                    (NML-1 (-NONE-:[1313..1313] *P*))
                    (CD:[1314..1316] 61)))))))))
    (.:[1316..1317] .)))

;sentence 9 Span:1318..1397
;Patients  were followed for periods of up to 4 years or until death
;supervened.
(SENT
  (S
    (NP-SBJ-1 (NNS:[1318..1326] Patients))
    (VP (VBD:[1328..1332] were)
      (VP (VBN:[1333..1341] followed)
        (NP-1 (-NONE-:[1341..1341] *))
        (UCP-TMP
          (PP (IN:[1342..1345] for)
            (NP
              (NP (NNS:[1346..1353] periods))
              (PP (IN:[1354..1356] of)
                (NP
                  (QP (IN:[1357..1359] up) (TO:[1360..1362] to)
                      (CD:[1363..1364] 4))
                  (NNS:[1365..1370] years)))))
          (CC:[1371..1373] or)
          (SBAR (IN:[1374..1379] until)
            (S
              (NP-SBJ (NN:[1380..1385] death))
              (VP (VBD:[1386..1396] supervened)))))))
    (.:[1396..1397] .)))

;sentence 10 Span:1398..1560
;Patients  exhibiting ras mutations were no more likely to develop AML
;compared to  ras-negative patients (1/3 vs. 10/24) or to have decreased
;survival (p = 0.64).
;[1419..1422]:gene-rna:"ras"
;[1464..1467]:malignancy:"AML"
;[1481..1484]:gene-rna:"ras"
(SENT
  (S
    (NP-SBJ-1
      (NP (NNS:[1398..1406] Patients))
      (VP (VBG:[1408..1418] exhibiting)
        (NP (NN:[1419..1422] ras) (NNS:[1423..1432] mutations))))
    (VP (VBD:[1433..1437] were)
      (ADJP-PRD (DT:[1438..1440] no) (RBR:[1441..1445] more)
                (JJ:[1446..1452] likely)
        (S
          (NP-SBJ-1 (-NONE-:[1452..1452] *))
          (VP
            (VP (TO:[1453..1455] to)
              (VP (VB:[1456..1463] develop)
                (NP (NN:[1464..1467] AML))
                (S-ADV
                  (NP-SBJ-2 (-NONE-:[1467..1467] *))
                  (VP (VBN:[1468..1476] compared)
                    (NP-2 (-NONE-:[1476..1476] *))
                    (PP-CLR (TO:[1477..1479] to)
                      (NP
                        (ADJP (NN:[1481..1484] ras) (HYPH:[1484..1485] -)
                              (JJ:[1485..1493] negative))
                        (NNS:[1494..1502] patients)))
                    (PRN (-LRB-:[1503..1504] -LRB-)
                      (NP
                        (NP
                          (NP (CD:[1504..1505] 1))
                          (PP (SYM:[1505..1506] /)
                            (NP (CD:[1506..1507] 3))))
                        (PP (IN:[1508..1511] vs.)
                          (NP
                            (NP (CD:[1512..1514] 10))
                            (PP (SYM:[1514..1515] /)
                              (NP (CD:[1515..1517] 24))))))
                      (-RRB-:[1517..1518] -RRB-))))))
            (CC:[1519..1521] or)
            (VP (TO:[1522..1524] to)
              (VP (VB:[1525..1529] have)
                (NP (JJ:[1530..1539] decreased) (NN:[1540..1548] survival)
                  (PRN (-LRB-:[1549..1550] -LRB-)
                    (S
                      (NP-SBJ (NN:[1550..1551] p))
                      (VP (SYM:[1552..1553] =)
                        (NP (CD:[1554..1558] 0.64))))
                    (-RRB-:[1558..1559] -RRB-)))))))))
    (.:[1559..1560] .)))

;sentence 11 Span:1562..1751
;These data indicate that, in this group of MDS patients, ras mutations do not
; appear to correlate with a poor prognosis, and do not adversely interact
;with  exogenously administered G-CSF.
;[1605..1608]:malignancy:"MDS"
;[1619..1622]:gene-rna:"ras"
;[1745..1750]:gene-protein:"G-CSF"
(SENT
  (S
    (NP-SBJ (DT:[1562..1567] These) (NNS:[1568..1572] data))
    (VP (VBP:[1573..1581] indicate)
      (SBAR (IN:[1582..1586] that) (,:[1586..1587] ,)
        (S
          (PP (IN:[1588..1590] in)
            (NP
              (NP (DT:[1591..1595] this) (NN:[1596..1601] group))
              (PP (IN:[1602..1604] of)
                (NP (NN:[1605..1608] MDS) (NNS:[1609..1617] patients)))))
          (,:[1617..1618] ,)
          (NP-SBJ-1 (NN:[1619..1622] ras) (NNS:[1623..1632] mutations))
          (VP
            (VP (VBP:[1633..1635] do) (RB:[1636..1639] not)
              (VP (VB:[1641..1647] appear)
                (S
                  (NP-SBJ-1 (-NONE-:[1647..1647] *))
                  (VP (TO:[1648..1650] to)
                    (VP (VB:[1651..1660] correlate)
                      (PP-CLR (IN:[1661..1665] with)
                        (NP (DT:[1666..1667] a) (JJ:[1668..1672] poor)
                            (NN:[1673..1682] prognosis))))))))
            (,:[1682..1683] ,) (CC:[1684..1687] and)
            (VP (VBP:[1688..1690] do) (RB:[1691..1694] not)
              (ADVP (RB:[1695..1704] adversely))
              (VP (VB:[1705..1713] interact)
                (PP-CLR (IN:[1714..1718] with)
                  (NP
                    (ADJP (RB:[1720..1731] exogenously)
                          (VBN:[1732..1744] administered))
                    (NN:[1745..1750] G-CSF)))))))))
    (.:[1750..1751] .)))

;section 12 Span:1755..1799
;PMID: 7512175 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1755..1759] PMID) (::[1759..1760] :) (CD:[1761..1768] 7512175)
        (NN:[1769..1770] -LSB-) (NNP:[1770..1776] PubMed) (::[1777..1778] -)
        (NN:[1779..1786] indexed) (IN:[1787..1790] for)
        (NNP:[1791..1799] MEDLINE-RSB-)))
